Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor [Yahoo! Finance]
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
Prelude Therapeutics (NASDAQ:PRLD) was downgraded by analysts at
Wall St
Prelude Therapeutics (NASDAQ:PRLD) was upgraded by analysts at
Wall Stre
Prelude Therapeutics Incorporated's (NASDAQ:PRLD) Path To Profitability [Yahoo! Finance]